All In Biotech

Drug Trial Radar · NCT05297045

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Oral RGT001-075 in Adult Patients With Uncontrollable Type 2 Diabetes Mellitus on Metformin Therapy

Last checked: Nov 20, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

17

Actual

Start

Mar 29, 2022

Primary completion

May 30, 2023

Study completion May 30, 2023

Sponsor

Lead sponsor
Regor Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Mar 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • RGT001-075Drug

    Oral GLP1 Receptor Agonist

  • PlaceboOther

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c from baseline to end of treatment in the modified intent-to-treat populationTime frame: up to 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Axon Clinical Research

    Doral, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.